Focus Partners Advisor Solutions LLC Grows Stock Position in AstraZeneca PLC $AZN

Focus Partners Advisor Solutions LLC increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 53.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,307 shares of the company’s stock after acquiring an additional 3,604 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in AstraZeneca were worth $875,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Cobblestone Capital Advisors LLC NY grew its position in AstraZeneca by 12.9% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 3,582 shares of the company’s stock worth $275,000 after acquiring an additional 408 shares during the last quarter. Fisher Asset Management LLC lifted its position in AstraZeneca by 2.3% in the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock valued at $1,623,604,000 after purchasing an additional 466,745 shares during the last quarter. Finemark National Bank & Trust bought a new stake in AstraZeneca in the third quarter valued at approximately $218,000. Arete Wealth Advisors LLC boosted its stake in shares of AstraZeneca by 9.1% during the third quarter. Arete Wealth Advisors LLC now owns 8,694 shares of the company’s stock valued at $671,000 after purchasing an additional 727 shares during the period. Finally, Aprio Wealth Management LLC grew its holdings in shares of AstraZeneca by 47.2% in the third quarter. Aprio Wealth Management LLC now owns 5,649 shares of the company’s stock worth $433,000 after purchasing an additional 1,812 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AZN has been the topic of several analyst reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a research note on Wednesday, December 3rd. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Citigroup assumed coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $194.44 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The company has a market cap of $301.56 billion, a PE ratio of 64.60, a P/E/G ratio of 1.59 and a beta of 0.32. The business has a 50 day moving average of $146.71 and a 200 day moving average of $106.43. AstraZeneca PLC has a 52 week low of $122.48 and a 52 week high of $212.71.

AstraZeneca Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be issued a $1.595 dividend. The ex-dividend date is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s dividend payout ratio is 66.26%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.